[Retracted] Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo

Figure 3

Comparison of in vitro antileukemic effects of parallel CAR19/20 T-cells with single or tandem CARs: (a) cell proliferation of N.T., parallel CAR19/20-3, CAR19, CAR20, or tandem CAR19/20-T cells cultured in X-VIVO 15 medium for 13 days; (b–d) CAR T-cells were cocultured with luciferase-expressing Raji (Raji-luc) (b), CD19⁺-K562 (c), and CD20⁺-K562 (d) cells for 18–24 h at different ratios (1:1, 5:1, 10:1, or 20:1). Percentage of specific cell lysis = (the luciferase activity of untreated tumor cells − the luciferase activity of CAR T-cell-treated tumor cells)/the luciferase activity of untreated tumor cells × 100; and (e) ELISA was performed to measure cytokine production of CAR T-cells at 24 h after coincubation with Raji cells at an E:T ratio of 10:1. Data are expressed as the mean ± SD; , ; n.s., nonsignificant; n = 3.

(a)

(b)

(c)

(d)

(e)